Intra-Cellular Looks to Raise $500M in Public Offering Following Phase III MDD Win

Following a victory in a late-stage major depressive disorder trial, Intra-Cellular Therapies is out to raise capital. The biopharma announced Thursday it is offering over 6.8 million shares at $73 a piece in a $500 million public offering.